Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Jafari et al1 should be congratulated on their timely report of the short-term morbidity and mortality of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in this issue of JAMA Surgery. Their data highlight the low mortality and acceptable morbidity from American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) hospitals. Moreover, these outcomes are important because they relate the experience of a broad spectrum of centers performing this radical intervention. However, what the study lacks are the answers to the unresolved questions and controversies regarding optimal patient selection and methodology of HIPEC.
Arrington AK, Kim J. Data From ACS NSQIP on CRS-HIPECCan They Cool Off the Controversies?. JAMA Surg. 2014;149(2):176. doi:10.1001/jamasurg.2013.3665